Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Dorrell
Andrew James Dorrell, East Blaxland AU
| Patent application number | Description | Published |
|---|---|---|
| 20090087119 | METHOD AND APPARATUS FOR ARBITRARY RATIO IMAGE REDUCTION - Disclosed is a method for re-sampling an input image comprising input samples to produce an output image comprising output samples. The method includes the following steps. A set of kernel values ( | 04-02-2009 |
| 20090161990 | ORIENTATION ADAPTED ALIASING CANCELLATION | 06-25-2009 |
| 20090322899 | FAIL SAFE IMAGE PROCESSING APPARATUS - Methods of capturing image pixel data representing a scene may be practiced using a camera and may be implemented as software, such as an application program executing within the camera. The methods are particularly advantageous where user modification to the camera control parameters leads to a difference between the values of the pre-capture control parameters for the camera when compared to the pre-capture control parameters that the camera would determine in fully automatic mode. The measured difference may be compared to one or more predetermined threshold values. | 12-31-2009 |
| 20100245602 | METHOD OF REMOVING AN ARTEFACT FROM AN IMAGE - A method of removing an artefact from an image captured with a motion invariant camera is disclosed. The captured image is de-blurred using a spatially invariant blur kernel. An edge filter with a fixed offset is applied to the de-blurred image to identify the location of at least one artefact. A parameter is estimated based on a region either side of the identified location. The at least one artefact is removed from the de-blurred image using the parameter. | 09-30-2010 |
Craig Dorrell, Portland, OR US
| Patent application number | Description | Published |
|---|---|---|
| 20090098140 | MONOCLONAL ANTIBODIES AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human ductal cells. Humanized forms of these antibodies, and functional fragments of these antibodies, are also disclosed. The antibodies can be conjugated to an effector molecule, such as a detectable marker, a therapeutic agent, or a toxin. These antibodies are of use to detect and isolate pancreatic cells or a subset thereof. The antibodies can be used for in vitro or in vivo detection and/or isolation of pancreatic endocrine cells. Methods of treating a pancreatic tumor are also disclosed. In several examples, the isolated monoclonal antibodies bind pancreatic endocrine cells and can be used to detect diabetes or a pancreatic endocrine cell tumor. | 04-16-2009 |
| 20110165080 | MONOCLONAL ANTIBODIES AND THEIR USE - Isolated monoclonal antibodies are disclosed herein that specifically bind a cell surface antigen expressed on the human pancreatic endocrine cells or a subset thereof, and/or a precursor thereof. Isolated monoclonal antibodies are also disclosed herein that specifically bind a cell surface antigen expressed on human pancreatic exocrine cells or human ductal cells. Humanized forms of these antibodies, and functional fragments of these antibodies, are also disclosed. The antibodies can be conjugated to an effector molecule, such as a detectable marker, a therapeutic agent, or a toxin. These antibodies are of use to detect and isolate pancreatic cells or a subset thereof. The antibodies can be used for in vitro or in vivo detection and/or isolation of pancreatic endocrine cells. Methods of treating a pancreatic tumor are also disclosed. In several examples, the isolated monoclonal antibodies bind pancreatic endocrine cells and can be used to detect diabetes or a pancreatic endocrine cell tumor. | 07-07-2011 |
Michael I. Dorrell, San Diego, CA US
| Patent application number | Description | Published |
|---|---|---|
| 20090124538 | Selective R-cadherin antagonists and methods - An isolated peptide useful as a selective antagonist of mammalian R-cadherin comprises 3 to 30 amino acid residues, three contiguous residues of the peptide having the amino acid sequence Ile-Xaa-Ser; wherein Xaa is an amino acid residue selected from the group consisting of Asp, Asn, Glu, and Gln. Preferably Xaa is Asp or Asn. In one preferred embodiment the peptide is a cyclic peptide having 3 to 10 amino acid residues arranged in a ring. The selective R-cadherin antagonist peptides of the invention are useful for inhibiting the targeting of stem cells, such as endothelial precursor cells, to developing vasculature, for inhibiting R-cadherin mediated cellular adhesion, and for inhibiting retinal angiogenesis. | 05-14-2009 |
| 20090285792 | Compositions and methods for treatment of neovascular diseases - The present invention provides compositions and methods of treating neovascular diseases, such as a retinal neovascular diseases and tumors, by administering to a patient suffering from a neovascular disease or tumor a vascular development inhibiting amount of a combination of the angiogenesis suppressing drugs comprising an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one compound selected from the group consisting of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor. Compositions for use in the methods include an admixture of an angiostatic fragment of tryptophanyl-tRNA synthetase (TrpRS) and at least one of a vascular endothelial growth factor (VEGF) signaling inhibitor and an integrin signaling inhibitor, together with a pharmaceutically acceptable excipient. | 11-19-2009 |
Wade C. Dorrell, Boise, ID US
| Patent application number | Description | Published |
|---|---|---|
| 20090287675 | Extending OLAP Navigation Employing Analytic Workflows - Analytic workflows for performing data analysis and other related operations are stored in an analytic workflow library and provided to a user upon selection of data from a data store. A workflow manager may rank the workflows based on a number of ranking algorithms prior to presentation. User selected workflows are executed in conjunction with relevant external applications and the analysis result provided to the user through the user's client application used to select the data. Workflows and associated interfaces may be received from a variety of sources and integrated into the workflow framework for enhancing data analysis. | 11-19-2009 |
| 20100262678 | CONFIGURATION OF A SINGLE-PURPOSE APPLICATION VIA A WEB APPLICATION - Architecture for providing easy and convenient configuration of a single-purpose application (SPA). A web-based SPA is retained on a client device for viewing specific information provided from a web server. A web-based identification component obtains an identity associated with the client device or device user. A website user interface enables the user to enter configuration information of the SPA. Subsequently, the configured SPA receives the requested information from the web server based on the identity. A storage component stores the configuration information on a remote web server and/or the client device for backup purposes. A communications component refreshes the requested information to provide updated information to the user via the SPA. | 10-14-2010 |